BioSpace News Archive

Analysis of data over a two-year period finds losing weight and minimizing weight regain can potentially lead to remission of type 2 diabetes

Interim clinical data to be presented at ADA 2019 show that approximately 85 percent of patients are insulin-free at six months after Revita DMR outpatient therapy

Study presented at ADA’s Scientific Sessions compared insulin-only mode of iLet to usual care

BioData has announced the roll-out of its Electronic Lab Notebook (ELN) platform, Labguru, with Inserm, France’s only public research institute to focus entirely on human health.

Abbott announced new data showing use of its FreeStyle Libre system, the company’s revolutionary continuous glucose monitoring technology, significantly reduced hemoglobin A1c levels for people living with Type 2 diabetes on intensive insulin therapy.

Study of more than 600 people over 25 years indicates lower blood pressure goals beneficial

Investigators from the Masonic Medical Research Institute, Weill Cornell Medicine and Beth Israel Deaconess Medical Center have identified the molecular mechanisms by which RAF1 mutations in patients with Noonan Syndrome cause hypertrophic cardiomyopathy, a dangerous thickening of the heart muscle that can lead to heart failure and death.

Patient-centered research and clinical studies coupled with device data provide new insights for improving outcomes and quality of life for people living with type 1 diabetes

Results from several studies of Eli Lilly and Company’s investigational dual GIP and GLP-1 receptor agonist, tirzepatide, reinforce its potential in lowering A1C and body weight in people with type 2 diabetes.

Cumulative three-year incidence rate of type 2 diabetes drops to 4%, according to PREVIEW intervention study presented at the ADA’s Scientific Sessions